Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct 29:2014:701493.
doi: 10.1155/2014/701493. eCollection 2014.

Target Therapy in Hematological Malignances: New Monoclonal Antibodies

Monika Podhorecka  1 , Justyna Markowicz  2 , Agnieszka Szymczyk  1 , Johannes Pawlowski  2
Affiliations
Review

Target Therapy in Hematological Malignances: New Monoclonal Antibodies

Monika Podhorecka et al. Int Sch Res Notices. .

Abstract

Apart from radio- and chemotherapy, monoclonal antibodies (MoAbs) represent a new, more selective tool in the treatment of hematological malignancies. MoAbs bind with the specific antigens of the tumors. This interaction is a basis for targeted therapies which exhibit few side effects and significant antitumor activity. This review provides an overview of the functional characteristics of MoAbs, with some examples of their clinical application. The promising results in the treatment of hematological malignancies have led to the more frequent usage of MoAbs in the therapy. Development of MoAbs is a subject of extensive research. They are a promising method of cancer treatment in the future.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Walawski J. Nowe leki i nowe podejście do leczenia a przeżycie chorych na nowotwory układu chłonnego. Onkologia w Praktyce Klinicznej. 2008;4(3):93–100.
    1. Wróbel T. Przeciwciała monoklonalne anty-CD20 w terapii chłoniaków agresywnych. Hematologia. 2010;1(4):342–351.
    1. Huszno J., Nowara E., Suwiński R. Rola polimorfizmów genowych w terapii przeciwnowotworowej ukierunkowanej na cele molekularne—przeciwciała monoklonalne. Onkologia Polska. 2011;14(3):146–151.
    1. Powroźnik B., Kubowicz P., Pękala E. Przeciwciała monoklonalne w terapii celowanej. Postępy Higieny i Medycyny Doświadczalnej. 2012;66:663–673. - PubMed
    1. Kobayashi Y. Molecular target therapy in hematological malignancy: front-runners and prototypes of small molecule and antibody therapy. Japanese Journal of Clinical Oncology. 2011;41(2):157–164. doi: 10.1093/jjco/hyq189. - DOI - PubMed